Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"InfoRLife SA","sponsor":"Navamedic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Navamedic ASA Acquires Innovative Antibiotic Product for Hospital Use in The Nordic Region","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Clindamycin

    Menu

    Clindamycin

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ortho Dermatologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel

              Details:

              IDP-126 (clindamycin 1.2%, adapalene 0.15%, benzoyl peroxide 3.1%) gel has the potential to be the first of its kind fixed dose triple combination treatment for acne vulgaris by inhibiting bacterial protein synthesis.

              Lead Product(s): Clindamycin Hydrochloride,Adapalene,Benzoyl Peroxide

              Therapeutic Area: Dermatology Product Name: IDP-126

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glenmark Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glenmark Pharmaceuticals Receives ANDA Approval for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg

              Details:

              Clindamycin hydrochloride is a bacteriostatic which inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome.

              Lead Product(s): Clindamycin Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: Cleocin-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              InfoRLife SA

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Navamedic ASA Acquires Innovative Antibiotic Product for Hospital Use in The Nordic Region

              Details:

              Clindamycin is a well-established antibiotic used in treatment of severe infections, including staphylococcal bone and joint infections, chronic sinusitis and infections of the lower respiratory tract.

              Lead Product(s): Clindamycin Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: Clindamycin-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Navamedic

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Rochem Clindamycin Hydrochloride
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Close
              4
              Post Enquiry
              POST ENQUIRY